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Chlamydia trachomatis can enter a viable but nonculturable state in vitro termed persistence. A common feature of C. tracho-
matis persistence models is that reticulate bodies fail to divide andmake few infectious progeny until the persistence-inducing
stressor is removed. Onemodel of persistence that has relevance to human disease involves tryptophan limitationmediated by
the host enzyme indoleamine 2,3-dioxygenase, which converts L-tryptophan toN-formylkynurenine. Genital C. trachomatis
strains can counter tryptophan limitation because they encode a tryptophan-synthesizing enzyme. Tryptophan synthase is the
only enzyme that has been confirmed to play a role in interferon gamma (IFN-)-induced persistence, although profound
changes in chlamydial physiology and gene expression occur in the presence of persistence-inducing stressors. Thus, we screened
a population of mutagenized C. trachomatis strains for mutants that failed to reactivate from IFN--induced persistence. Six
mutants were identified, and the mutations linked to the persistence phenotype in three of these were successfully mapped. One
mutant had a missense mutation in tryptophan synthase; however, this mutant behaved differently from previously described
synthase null mutants. Two hypothetical genes of unknown function, ctl0225 and ctl0694, were also identified andmay be in-
volved in amino acid transport and DNA damage repair, respectively. Our results indicate that C. trachomatis utilizes function-
ally diverse genes to mediate survival during and reactivation from persistence in HeLa cells.
Chlamydia trachomatis has a characteristic biphasic develop-mental cycle in cell culture (1). The two dominant chlamydial
forms are elementary bodies (EBs) and reticulate bodies (RBs) (1).
EBs represent the infectious, nonreplicative form capable of in-
vading host cells (1). Following entry, EBs differentiate into RBs
that replicate inside parasitophorous vacuoles termed inclusions
(1). Maturing RBs then redifferentiate back to EBs and exit the
host cell via lysis or extrusion (2). Morphologically aberrant RBs
have been observed in clinical specimens (3). This abnormal de-
velopmental cycle can be recapitulated in a laboratory setting by
exposingC. trachomatis to various stressors such as host cytokines
(4–6), excess amino acids (7), iron deficiency (8, 9), virus coinfec-
tions (10), and antibiotics (11, 12) (reviewed in reference 13).
Under these conditions, normal C. trachomatis RBs can transition
into persistent forms that do not divide, are enlarged, and have
aberrant morphology (13). Upon removal of the persistence-in-
ducing stressor, RBs transition back into normal RBs and con-
tinue normal development (13). Aberrant RB morphology is a
shared feature of multiple C. trachomatis persistence models and
may reflect activation of a common stress response program (13).
Thus, characterizing how C. trachomatis enters, survives, and re-
activates from persistence could reveal new insights into chlamy-
dial pathogenesis.
The Th1 cytokine interferon gamma (IFN-) can induce dif-
ferential expression of hundreds of interferon-stimulated (host)
genes (ISG), and the products of many of these genes can inhibit
intracellular pathogens (14, 15). Byrne and colleagues showed that
IFN- triggers C. psittaci and C. trachomatis persistence in T24
and HeLa 229 (HeLa) cells, respectively (6, 16). In these cells,
IFN- induces expression of indoleamine 2,3-dioxygenase
(IDO1), which converts the essential amino acid tryptophan to
N-formylkynurenine. It is hypothesized that this process starves
chlamydia of tryptophan because C. trachomatis RBs can be reac-
tivated when IFN- is removed or tryptophan is added to the cell
culture medium (6, 17).
Comparison of the C. trachomatis transcriptomes during IFN-
-induced persistence and reactivation in the presence of exoge-
nous tryptophan or indole revealed insights into the nature of C.
trachomatis persistence (18). Analysis of differentially expressed
genes suggested that metabolism in persistent RBs shifts toward
utilization of alternate nutrient sources and prevention of cellular
damage at the expense of RB proliferation and EB production
(18). For example, genes for tryptophan utilization and DNA re-
pair and the late gene repressor euo were upregulated in persistent
RBs (18). In contrast, genes encoding chlamydial histones, genes
corresponding to EB outer membrane complex formation, and
some cell division genes were downregulated (18). These data are
consistent with the suggestion that persistence is a stress response
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program that is triggered in response to amino acid starvation
(13).
Multiple lines of evidence suggest that IFN--induced persis-
tence and reactivation may be relevant to C. trachomatis genital
infections in humans. All reference C. trachomatis strains are in-
hibited by IFN- in human epithelial cells (19), but only the gen-
ital strains encode functional tryptophan synthase enzymes that
can synthesize tryptophan from serine and indole (20–24). Nei-
ther C. trachomatis bacteria nor humans produce indole, but var-
ious microorganisms that colonize the genital tract do (25–27).
Interestingly, the incidence of C. trachomatis infection is also ele-
vated in women with bacterial vaginosis (BV) (28), and the mi-
crobiomes of these women are often enriched with bacterial taxa
that contain indole producers, including Prevotella spp. (25, 28–
30). Moreover, indole can be detected in vaginal secretions from
women with BV and aberrant RBs were observed in cervical scrap-
ings from one patient with C. trachomatis (3). This specimen pro-
duced few infectious EBs but contained a highChlamydia genome
load, suggesting that most of the genomes corresponded to per-
sistent organisms (3). The observations described above suggest
that C. trachomatis genital strains may rely on microbiome-de-
rived indole to circumvent IDO1-mediated tryptophan depletion
(31, 32).
Tryptophan and indole similarly rescue C. trachomatis devel-
opment in some IFN- persistence models (20, 21, 33). In addi-
tion, IFN- is unable to trigger C. trachomatis persistence in
IDO1-deficient cells (34), confirming that the IDO1 gene is a key
antichlamydial ISG. However, there is substantial variation in the
IFN- sensitivity of isolates within subgroups of tryptophan syn-
thase-positive genital strains (19) and tryptophan synthase-nega-
tive trachoma strains (35). It has been reported that interferon-
stimulated p65 guanylate binding proteins (GBP) may contribute
to IFN--mediated control of C. trachomatis in HeLa cells (36)
and macrophages (37), although more recent results indicate that
human GBP1 (hGBP1) does not localize to C. trachomatis vacu-
oles and is dispensable for cell-autonomous control of this patho-
gen in both unprimed and IFN--primed human cells (38). Thus,
there is evidence that both the antichlamydial effects of IFN- and
the C. trachomatis response could involve more than host-patho-
gen tryptophan competition.
In this study, we sought to expand upon the classical view of
chlamydial persistence by identifying additional C. trachomatis
genes outside the tryptophan synthase operon that mediate entry
into, survival during, and reactivation from IFN--induced per-
sistence. Thus, a loss-of-function screen was used to identify C.
trachomatis mutants that have decreased survival following in-
dole-mediated reactivation of IFN--induced persistence in HeLa
cells. Our results suggest thatC. trachomatisutilizes multiple strat-
egies to allow it to survive during and reactivate from persistence.
MATERIALS AND METHODS
Cell culture and Chlamydia propagation. McCoy and HeLa cells were
obtained from the American Type Culture Collection and were cultivated
in Dulbecco’s modified Eagle’s medium (DMEM)– high-glucose medium
supplemented with 4 mM L-glutamine (HyClone), 10% fetal bovine se-
rum (FBS; Atlanta Biologicals), sodium pyruvate (HyClone), HEPES
(HyClone), and nonessential amino acids (Gibco) (DMEM-10). The cells
were grown in 5% CO2 humidified incubators at 37°C, as described pre-
viously (39). C. trachomatis L2-GFP (L2-green fluorescent protein) was
created by transforming C. trachomatis L2 434/Bu (C. trachomatis) with
pGFP::SW2 (a kind gift from Ian Clarke, University of Southampton,
United Kingdom) (40). Mutant screens were performed using a library of
plaque-cloned ethane methylsulfonate (EMS)-mutagenized L2-GFP iso-
lates (41).
Screen for Sip mutants. The strategy for the Sip (sensitive to IFN--
induced persistence) mutant screen is depicted in Fig. 1A. HeLa cells were
seeded in two replicate 96-well plates in DMEM-10. The following day,
the medium was replaced with fresh DMEM-10 or DMEM-10 supple-
mented with 10 ng/ml IFN- (Thermo Fisher) (DMEM-10G) and the
monolayers were incubated for 24 h. The untreated and IFN--treated
monolayers were then infected with equal volumes of mutant library iso-
lates in sucrose-phosphate glutamic acid buffer (0.25 M sucrose, 10 mM
phosphate, 5 mM L-glutamic acid, pH 7.2 [SPG]) by centrifugation at
1,600 g for 1 h followed by rocking for 30 min at 37°C (centrifugation
and rocking). The SPG was aspirated, and DMEM-10 or DMEM-10G was
added. Untreated monolayers were fixed at 24 h postinfection (hpi) in
3.7% formaldehyde. IFN--treated monolayers were rinsed with phos-
phate-buffered saline (PBS) at 24 hpi and then incubated for an additional
24 h in tryptophan-free DMEM-10 (UCSF Cell Culture Facility)–10%
dialyzed FBS (DMEM-10TF)–10M indole. The experimental infections
were fixed in 3.7% formaldehyde at 24 h postreactivation. Fluorescent
inclusions were imaged using an automatic EVOS inverted fluorescence
microscope at 4 magnification using a GFP filter set. Inclusions were
counted using a custom program developed in FIJI (42).
One-step growth curve analysis. HeLa cell monolayers were infected
at a multiplicity of infection (MOI) of 0.1 and then were incubated in
DMEM-10 until the indicated time points. Monolayers were harvested in
SPG by freeze-thaw and bead agitation (43). Serial dilutions of these
lysates were used to infect fresh HeLa cells by centrifugation and rocking,
and the cells were then methanol fixed at 36 hpi. Inclusions were labeled
FIG 1 IFN- persistence screen. (A) Untreated and IFN--treated HeLa cell
monolayers were infected with equal volumes of isolates from an EMS-mu-
tagenized L2-GFP library. Untreated monolayers were fixed at 24 hpi. Indole
was added to the IFN--treated monolayers at 24 hpi to reactivate persistentC.
trachomatis. Monolayers were fixed 24 h later. (B) Secondary screening of each
persistence mutant. The inclusions that each purified isolate formed under the
untreated and IFN--treated conditions were counted and used to calculate a
ratio. This ratio was compared to the value determined with L2-GFP. Sip
mutants had significantly increased untreated/IFN--treated inclusion ratios
compared to L2-GFP. The graph depicts the mean of the results of three ex-
periments performed in triplicate. Error bars indicate standard deviations
(SD). ***, P 0.001; ****, P 0.0001.
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with an antichlamydial lipopolysaccharide (LPS) antibody (EVIH1), a
kind gift from Harlan Caldwell (National Institutes of Health, Bethesda,
MD), and with a secondary Dylight 488-conjugated anti-mouse IgG. In-
clusions were imaged at 4magnification as described above.
Indole and tryptophan reactivation assays. HeLa cells were seeded
and treated with IFN- as described for the Sip mutant screen. Monolay-
ers were infected with an MOI of 0.1 for each strain. The infections were
reactivated by adding fresh DMEM-TF, supplemented with either 10M
indole or 128 mg/liter tryptophan, and then incubated for 24 h. For in-
clusion-forming-unit (IFU) assays, the infected monolayers were fixed in
3.7% formaldehyde at 24 hpi for the untreated plate or 24 h postreactiva-
tion for the IFN--treated plate. When inclusion cross-sectional areas
were determined, infected monolayers were first fixed with 3.7% formal-
dehyde and then permeabilized with 100% methanol and labeled with
EVIH1 as described above. For infectious-progeny assays, EBs were re-
leased from monolayers by freeze-thaw in SPG and bead agitation. Serial
dilutions of these lysates were used to infect fresh HeLa cells by centrifu-
gation and rocking, and these infection reaction mixtures were fixed with
methanol at 36 hpi. Inclusions were labeled with EVIH1 and Dylight 488-
conjugated anti-mouse IgG. Inclusions were imaged at 20 (cross-sec-
tional-area determinations) or 4 (infectious progeny assays) magnifica-
tion as described above.
Recombination andmutationmapping. HeLa cell monolayers in 12-
well plates were infected with pairs of mutants, each at an MOI of 2, or
with individual mutants at an MOI of 4 by centrifugation and rocking and
were incubated in DMEM-10. The infected monolayers were lysed at 24
hpi in SPG by bead agitation. The lysates were used to infect HeLa cell
monolayers that had been preincubated in DMEM-10G for 24 h by cen-
trifugation and rocking. The infections were then incubated in DMEM-
10G for 24 h, and then the medium was replaced with DMEM-10TF
supplemented with 10 M indole, and the infections were incubated for
an additional 24 h. Lysates were prepared in SPG at 48 hpi by bead agita-
tion. This process was repeated until populations of IFN--resistant re-
combinant strains expanded in individual wells or was halted after 5
rounds if no inclusions were observed. Populations of isolates from the
wells that contained IFN--resistant populations were subsequently
plaque cloned (44) and expanded in HeLa cells, and mutations were con-
firmed by DNA sequencing.
DNA sequencing. HeLa cells infected with various mutants were har-
vested by bead agitation in SPG, and the lysate was clarified by centrifu-
gation at 500 g for 20 min. Host cell genomes were depleted by DNase
treatment (45), and the remaining DNA was amplified with REPLI-g
(Qiagen) according to the manufacturer’s instructions. Whole-genome
sequencing (WGS) libraries were prepared using a Nextera XT DNA li-
brary preparation kit according to the manufacturer’s instructions. Sin-
gle-end 100-bp sequencing was performed on an Illumina HiSeq 2000
sequencing system at the Center for Genomic Research and Biocomput-
ing Core, Oregon State University, Corvallis, OR. Genome sequences were
assembled and analyzed as described previously (45). Mutations were
confirmed by PCR amplification of the corresponding genomic regions
and Sanger sequencing.
IFN- sensitivity assays. HeLa cell monolayers were incubated in
DMEM-10G for 24 h, infected with the indicated strains at an MOI of 0.1,
and then incubated in DMEM-10TF supplemented with IFN- and 128
mg/liter tryptophan. The monolayers were fixed at 24 hpi with 3.7%
formaldehyde and imaged to count inclusions. The monolayers were then
permeabilized with 100% methanol. Inclusions were labeled with anti-
bodies, and the cross-sectional areas were determined as described above.
Transmission electron microscopy. HeLa cells were infected at an
MOI of 0.1 with various strains as described for the mutant screen. The
monolayers were fixed 24 h postinfection or 24 h postreactivation with
indole using 2.5% glutaraldehyde and 4% formaldehyde. Samples were
stained with 1% osmium tetroxide and 1% tannic acid, dehydrated, and
embedded in epoxy resin. Ultrathin sections were generated using an
ultracut UCT ultramicrotome (Leica) and stained with uranyl acetate and
lead citrate. Sections were imaged using a JEOL JEM 1010 microscope
with a Gatan 890 4,000-by-4,000-pixel digital camera at the Indiana Uni-
versity Electron Microscopy Center in Bloomington, IN.
Quantitative real-time PCR. A gMAX minikit (IBI Scientific) was
used according to the manufacturer’s instructions to purify DNA from
infected cells pre- and post-indole or -tryptophan reactivation at various
times. The DNA was mixed with FastStart TaqMan Probe Master mix
(Roche) and 9 pmol of primers 5=-GTAGCGGTGAAATGCGTAGA-3=
and 5=-CGCCTTAGCGTCAGGTATAAA-3= and a 5=-6-carboxyfluores-
cein (FAM)-ATGTGGAAG/ZEN quencher/AACACCAGT-3= probe tar-
geting the C. trachomatis 16S rRNA gene. Quantitative PCR was per-
formed on an Eppendorf Realplex4 device. Standard curves were
generated using a cloned copy of the C. trachomatis 16S rRNA gene.
Cycling conditions were as follows: 10 min at 95°C, followed by 40 cycles
of 95°C for 20 s, 60°C for 1 min, and 68°C for 20 s.
Tryptophan-free reactivation assays. HeLa cells were seeded in
DMEM-10. The following day, monolayers were rinsed with PBS and the
medium was replaced with fresh DMEM-10 or DMEM-10TF. Twenty-
four hours later, the monolayers were infected at an MOI of 0.1 as de-
scribed above. The infections performed in DMEM-10 were fixed at 24
hpi. In contrast, infections incubated in DMEM-10TF were rinsed with
PBS for 24 hpi and then incubated for an additional 24 h in either DMEM-
10TF–10 M indole or DMEM-10 and fixed at 48 hpi. Inclusions were
measured and ratios were calculated and compared to L2-GFP results as
described above.
Isoleucine sensitivity assay. HeLa cells were seeded in DMEM-10 and
were infected at an MOI of 0.1 as described above. The infections were
then incubated in DMEM-10 supplemented with a range of concentra-
tions of isoleucine. The infected monolayers were fixed at 44 hpi and
permeabilized with methanol. The cross-sectional areas of inclusions
were determined as described above.
Statistics. Data were analyzed using GraphPad Prism version 6.0 for
Windows. Statistics were calculated using one-way analysis of variance
(ANOVA) and Dunnett’s post hoc test for multiple comparisons.
RESULTS
Screen for IFN- persistence and reactivation mutants. We
screened a nonsaturating library of 2,016 chemically mutagenized
L2-GFP isolates for mutants that had a reduced ability to be indole
reactivated from IFN--induced persistence in HeLa cells (Fig.
1A). First, the ratio of inclusions each library isolate formed in
untreated HeLa cells at 24 hpi and in IFN--plus-indole-treated
HeLa cells at 48 hpi was calculated. In order to normalize for the
differing MOIs of the infections with the different library isolates,
this ratio was compared to the ratio of inclusions that the parent
L2-GFP strain formed under the same sets of two conditions. Sim-
ilar to previous studies, L2-GFP produced approximately 50% as
many inclusions in the IFN--plus-indole-treated HeLa cells as it
did in the untreated cells (data not shown) (18, 20). In contrast,
some library isolates formed dramatically fewer inclusions in the
IFN--plus-indole-treated cells than in the untreated cells, and
the phenotypes of six of these mutant isolates were verified in a
secondary screen (Fig. 1B). One-step growth curve analysis was
used to compare the developmental kinetics of L2-GFP and these
six mutant isolates (Fig. 2). The number of EBs produced by each
of the mutants in cells not treated with IFN- was indistinguish-
able from the number produced by L2-GFP in untreated HeLa
cells. These results indicated that the phenotypes of the six mutant
strains were not measurably compromised in fitness and that the
mutant phenotypes are related to their inability to enter into, sur-
vive during, and/or be reactivated from IFN- persistence. We
named these isolates Sip mutants on the basis of the observation
that they were sensitive to IFN--induced persistence.
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Allele mapping uncovers novel persistence genes. A whole-
genome sequencing approach was used to compare the genome
sequences of the Sip mutants and L2-GFP. Each Sip mutant had
between 2 to 8 mutations and contained at least two nonsynony-
mous substitutions in predicted coding sequences (Table 1). None
of the polymorphisms in the different mutants were located in the
same genes or operons. This prevented us from linking specific
mutations to the phenotypes of the mutants. However, Sip1 had a
missense mutation in trpB, which encodes the beta subunit of
tryptophan synthase. A mutation in this gene was expected and is
a key datum that validates the efficacy of the screen we developed.
We attempted to identify the causative mutations in the Sip
mutants using a counterselection lateral gene transfer (LGT) ap-
proach which takes advantage of detrimental alleles and uses them
for selection. This technique produces markerless recombinants
that have swapped the detrimental mutant allele for a wild-type
copy (41). HeLa cells were coinfected with different pairs of the
Sip mutants, and then coinfections were repeatedly passaged in
HeLa cells cultivated under the persistence screen conditions.
Phenotypic revertants arose from three of the coinfection experi-
ments (Sip1 Sip2, Sip1 Sip6, and Sip2 Sip6). In contrast, no
revertants arose in control infections in which twice-as-large in-
oculums of individual Sip mutants were passaged (data not
shown). This indicated that the IFN--resistant isolates resulted
from recombination and loss of the detrimental causative allele
and were not genetic revertants or suppressor mutants. L2-GFP
and recombinant Sip (rSip) strains produced similar numbers of
FIG2 Sip mutants exhibit normal growth kinetics. HeLa cell monolayers were
infected with L2-GFP or Sip mutants. Monolayers were harvested at various
times postinfection, and these lysates were used to infect fresh HeLa cells. The
number of inclusions each isolate formed was then normalized to the inocu-
lum. The graph depicts the mean of the results of three experiments performed
in triplicate. Error bars indicate SD.
TABLE 1 Mutations in Sip mutantsa
Mutant strain Genome coordinate Ref. Mut. Codon Gene CTL locus CT locus
Sip1 (TrpBP221S) 43026 R R 818 CTL0033 CT664
166676 Y Y 341 groEL CTL0124 CT755
177906 A T 241 CTL0133 CT764
264602 D N 62 CTL0209 CT837
512700 P S 221 trpB CTL0423b CT170
Sip2 (CTL0225G77E) 173557 G R 298 ftsW CTL0129 CT760
281464 G E 77 CTL0225b CT852
290406 P P 258 cpa CTL0233 CT858
324317 V V 93 gatC CTL0257 CT002
404913 S F 365 CTL0325 CT069
505526 Intergenic
538379 G E 299 CTL0447 CT195
856877 L L 64 ispD CTL0722 CT463
Sip3 225552 S N 246 plsB CTL0176 CT807
248355 Intergenic
363762 L L 245 CTL0291 CT036
669764 P L 1128 rpoC CTL0566 CT314
Sip4 438375 G R 37 trxB CTL0354 CT99
450703 G R 14 groES CTL0366 CT111
528731 G E 39 tmk CTL0440 CT188
Sip5 222745 P S 831 ptr CTL0175 CT806
757859 H Y 37 CTL0641 CT385
Sip6 (CTL0694P105L) 202648 S F 71 CTL0157 CT789
311659 G G 39 pmpG CTL0250 CT871
387134 P S 225 CTL0312 CT56
435055 L L 381 nusA CTL0352 CT97
490946 D N 945 CTL0402 CT147
778955 R R 238 gltT CTL0658 CT401
823442 P L 105 CTL0694b CT435
870246 G G 296 CTL0737 CT476
a Ref., reference amino acid; Mut., mutant amino acid; CTL, C. trachomatis 434/Bu; CT, C. trachomatis D/UW-3/CX.
b Mapped persistence allele.
Muramatsu et al.
2794 iai.asm.org October 2016 Volume 84 Number 10Infection and Immunity
inclusions following indole reactivation (Fig. 3). Sanger sequenc-
ing revealed that each of the rSip isolates differed from one of its
two mutant parents by one nonsynonymous mutation. This
analysis linked nonsynonymous mutations in genes encoding
the beta subunit of tryptophan synthase (TrpB), a putative in-
tegral membrane protein (CTL0225), and a putative oxi-
doreductase (CTL0694) to the phenotypes of Sip1 (TrpBP221S),
Sip2 (CTL0225G77E), and Sip6 (CTL0694P105L), respectively (Ta-
ble 1). We focused our subsequent efforts on characterization of
the phenotypes of these mapped mutants.
Sipmutants can enter into apersistent state.Results from our
primary screen could not be used to determine whether Sip mu-
tants were compromised in their abilities to enter, survive during,
or reactivate from IFN- persistence. To address this issue, we
used established methods to examine each mutant and determine
at which step the mutation caused a defect in the development of
its persistence program. Light microscopy and transmission elec-
tron microscopy (TEM) were used to examine the inclusions of
the Sip mutants and the L2-GFP strain in untreated and IFN--
plus-indole-treated HeLa cells to determine if the Sip mutants had
a defect in entering persistence. Inclusions of the Sip mutants were
significantly (P 0.0001) smaller (but were not fragmented in the
manner observed in a prior study of severely tryptophan-starved
C. trachomatis [46]) than those of L2-GFP following reactivation,
despite being similar or larger in size under normal growth con-
ditions (Fig. 4A and B). No obvious differences in EB or RB mor-
phology were detected in the untreated HeLa cells, consistent with
the results of the one-step growth curve experiments (Fig. 2 and
5A to D). However, in IFN--plus-indole-treated HeLa cells, only
the inclusions of the Sip mutants still contained aberrant RBs (Fig.
5F to H) following reactivation, indicating that they maintained
the ability to enter persistence. In contrast, dividing RBs were
frequently observed in HeLa cells infected with L2-GFP (Fig. 5E).
As expected, dividing RBs were also observed in HeLa cells in-
fected with rSip strains (see Fig. S1 in the supplemental material).
These results suggested that the Sip mutants could enter persis-
tence but were impaired in their ability to survive during or to be
reactivated from persistence.
Sip mutants are not reactivated by tryptophan or indole.
Since the Sip mutants produced fewer inclusions, we also tested if
the remaining inclusions produced infectious EBs. We infected
untreated HeLa cells with lysates from IFN--plus-indole-treated
infections and counted inclusions at 34 hpi. All three of the Sip
mutant strains produced significantly (P  0.0001) fewer infec-
tious EBs than L2-GFP (Fig. 6A). This result confirmed that the
Sip mutant strains not only formed fewer inclusions but also were
impaired in their ability to produce infectious progeny.
FIG 3 Sip recombinants have wild-type persistence phenotypes. Recombi-
nant Sip isolates formed numbers of inclusions similar to those formed by
L2-GFP isolates in persistence reactivation experiments. Inclusion counts
from corresponding control and reactivation experiments were used to calcu-
late ratios for each isolate, and these ratios were compared to L2-GFP data. The
graph depicts the mean of the results of three experiments performed in trip-
licate. Error bars indicate SD. n.s., nonsignificant.
FIG 4 Sip mutants make smaller inclusions following reactivation. (A) L2-GFP and mapped Sip mutant inclusion morphology was examined by fluorescence
microscopy. Micrographs depict representative fields of GFP-positive (GFP) inclusions in untreated and in IFN--plus-indole-treated HeLa cells. (B and C)
The control (B) and reactivation (C) infections whose results are presented in panel A were fixed, and the inclusions were labeled with antibodies and imaged
at 20 to calculate their cross-sectional areas. At least 1,000 inclusions were measured for each strain and condition in each of three independent experiments.
Cross-sectional areas were compared to L2-GFP data, and the error bars indicate SD. ****, P 0.0001; n.s, nonsignificant.
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Next, we tested if the Sip mutants produced infectious EBs
following tryptophan reactivation to determine if the mutants had
defects in acquiring indole or converting indole to tryptophan. A
C. trachomatis trpB null mutant can be reactivated only with tryp-
tophan, whereas strains that encode a functional tryptophan syn-
thase can be reactivated by tryptophan or indole (47). Tryptophan
and indole similarly rescued L2-GFP EB production (Fig. 6), con-
sistent with the results of previous studies (20, 21, 33, 47). In
contrast, tryptophan had little effect on the EB production seen
with the Sip mutants (Fig. 6B). Surprisingly, even the TrpBP221S
mutant was not rescued by treatment with tryptophan. This sug-
gested that the defects of the Sip mutants were unrelated to tryp-
tophan metabolism and that the mutant trpB allele in the
TrpBP221S strain might produce a protein with an altered function.
Sipmutants are differentially sensitive to IFN-. Since IFN-
upregulates the expression of diverse ISG, we tested if the Sip
mutants could form inclusions in IFN--treated cells under tryp-
tophan-sufficient conditions. Untreated and IFN--treated HeLa
cells were independently infected with L2-GFP or the Sip mutants.
IFN- plus excess tryptophan were immediately added following
infection to prevent entry into persistence. The numbers of inclu-
sions formed (Fig. 7A) and their relative sizes (Fig. 7B) were as-
sessed 24 hpi. The TrpBP221S and CTL0225G77E mutants produced
slightly more inclusions than L2-GFP under the tryptophan-suf-
ficient conditions. Tryptophan represses the expression of trpAB,
and tryptophan treatment restored TrpBP221S strain inclusion for-
mation; thus, this result suggested that the mutant trpB allele in
the TrpBP221S strain was detrimental to chlamydial survival only
during persistence. The CTL0225G77E inclusions were signifi-
cantly larger (P 0.0001) than those seen with L2-GFP in IFN--
plus-tryptophan-treated cells. This is consistent with the
CTL0225G77E inclusions being significantly (P  0.0001) larger
than L2-GFP inclusions under normal growth conditions (Fig.
4B). In contrast, the numbers of inclusions seen with the
CTL0694P105L mutant were similar to the numbers of inclusions
seen with L2-GFP under these conditions but the inclusions were
significantly smaller (P  0.0001), indicating that a tryptophan-
independent effect of IFN-may partially affect the development
and subsequence size of CTL0694P105L inclusions during persis-
tence.
Genome replication during persistence. We next used quan-
titative PCR to measure and compare the rates of L2-GFP and Sip
mutant genome accumulation during IFN- treatment and reac-
tivation. Consistent with previous reports that C. trachomatis ge-
nome replication continues during persistence, albeit more slowly
(48), L2-GFP and Sip mutant genome copies slowly accumulated
from 2 to 24 h postinfection in IFN--treated HeLa cells. The
patterns of TrpBP221S genome accumulation diverged during in-
dole and tryptophan reactivation. The rate of accumulation of
genome copies of the TrpBP221S strain slightly increased 36 h after
indole addition (Fig. 8A) but increased approximately 5-fold dur-
ing the same interval after tryptophan addition (Fig. 8B). This
FIG 5 Sip mutant inclusions contain aberrant RBs. Transmission electron
microscopy was used to compare RB and EB morphologies in untreated (A to
D) and in IFN--plus-indole-treated (E to H) HeLa cells at 24 hpi and 24 h
postreactivation, respectively. Arrowheads indicate aberrant RBs.
FIG 6 Sip mutant EB production cannot be rescued by tryptophan or indole
treatment. IFN--treated HeLa cells were infected with L2-GFP or Sip mu-
tants, and then the infections were reactivated with (A) indole or (B) trypto-
phan. The infections were harvested 24 h postreactivation and the EBs in the
lysates enumerated in untreated HeLa cells. The number of inclusions that
each strain formed was normalized to the inoculum and was then compared to
L2-GFP data. The graph depicts the mean of the results of three experiments
performed in triplicate. The error bars indicate SD. ****, P 0.0001.
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result suggested that tryptophan, but not indole, was able to par-
tially mitigate the detrimental effects of TrpBP221S on genome ac-
cumulation. Genome accumulation of CTL0225G77E was de-
creased and delayed compared to the L2-GFP results during
indole and tryptophan reactivation, suggesting that this mutant
might be unable to exit persistence and resume rapid genome
replication. Finally, CTL0694P105L genome accumulation lagged
only slightly behind L2-GFP genome accumulation during reacti-
vation with indole and tryptophan. Considering the results of the
indole and tryptophan reactivation experiments, where the
CTL0694P105L strain formed aberrant RBs (Fig. 5H) and few in-
fectious EBs (Fig. 6), these results suggest that genome replication
is uncoupled from EB production during CTL0694P105L reactiva-
tion.
Sipmutants have similar phenotypes in low-tryptophan and
IFN--induced persistence models. It was unclear if the defects
in the Sip mutants in the IFN- persistence model were primarily
due to tryptophan depletion or were due to other effects of IFN-.
C. trachomatis also enters persistence in HeLa cells in the absence
of IFN- when tryptophan is limiting and can be reactivated later
by the addition of tryptophan or indole to the cell culture medium
(46). We compared the number of inclusions seen with L2-GFP,
the Sip mutants, and the Sip revertants formed under tryptophan-
replete conditions at 24 hpi to the number seen under tryptophan-
free conditions when we added tryptophan or indole 24 h postin-
fection and measured inclusions at 48 hpi. Inclusion formation
seen with all three of the mutants, but not that seen with L2-GFP
or the Sip revertants, was impaired to a degree similar to that
observed in the IFN- reactivation experiments under the trypto-
phan-free reactivation conditions (see Fig. S2 in the supplemental
material). These results suggested that tryptophan limitation was
the main factor that was responsible for the phenotypes of the Sip
mutants in the IFN- persistence model.
CTL0225may be an amino acid transporter.Addition of high
levels of some amino acids to the infection medium can cause C.
trachomatis to enter an alternate persistence-like state (7). In ex-
planation of this phenomenon, Braun et al. proposed that isoleu-
cine-mediated inhibition of C. trachomatis growth was mediated
by competition for the branched-chain amino acid transporter
BrnQ (49). In their system, excess isoleucine causedC. trachomatis
to form smaller inclusions that contained aberrant RBs. To further
differentiate the persistence phenotypes of the Sip mutants, we
compared the levels of sensitivity of the mutants to isoleucine
using a range of isoleucine concentrations. Addition of isoleu-
cine similarly reduced the sizes of the L2-GFP, TrpBP221S,
CTL0694P105L, and rSip2 strains in a dose-dependent manner. In
contrast, CTL0225G77E formed significantly (P 0.0001) smaller
inclusions at the same isoleucine concentrations (see Fig. S3 in the
supplemental material). This suggests that CTL0225 might func-
tion similarly to BrnQ.
DISCUSSION
Our results indicate that IFN- elicits multiple stresses that impact
C. trachomatis persistence. Since none of the mutants that we
identified had mutations in the same genes or operons, this indi-
cates that a limitation of our approach was that our screen did not
reach saturation. As expected, we were able to isolate a Sip mutant
that contained a mutation in tryptophan synthase. Additionally,
five other mutants were isolated that contained no mutations with
obvious links to tryptophan metabolism. Among these five, we
FIG 7 The IFN- sensitivity phenotypes of Sip mutants differ. Untreated and
IFN--treated HeLa cells were infected with L2-GFP or Sip mutants. Medium
supplemented with tryptophan and IFN-was added immediately after infec-
tion. (A) The number of inclusions that the Sip mutants formed in untreated
versus IFN--treated HeLa cells was converted to a ratio, and then the ratio
was compared to L2-GFP data. The graph depicts the mean of the results of
three experiments performed in triplicate. Error bars depict SD. *,P 0.05; **,
P  0.01; n.s., nonsignificant. (B) The cross-sectional areas of inclusions in
IFN--treated cells at 24 hpi. At least 1,000 inclusions were measured for each
strain in 2 experiments with 6 replicates, and the graph depicts the mean of the
results of each of the experiments. Error bars depict SD. ****, P 0.0001.
FIG 8 Genome replication is altered during Sip mutant reactivation. Genome
copy numbers of L2-GFP and the Sip mutants were characterized pre- and
post-indole (A) or -tryptophan (B) reactivation using primers and a probe set
targeting the C. trachomatis 16S rRNA gene. The arrows indicate the times of
indole or tryptophan addition. Data points represent the mean numbers of
genome copies from two experiments performed in duplicate. Circles,
L2-GFP; squares, TrpBP221S; triangles, CTL0225G77E; inverted triangles,
CTL0694P105L.
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were able to map the persistence gene in two Sip mutants, the
CTL0225G77E and CTL0694P105L mutants, using a counterselec-
tion LGT technique. We also attempted to map the Sip mutants
using an antibiotic-driven, positive-selection LGT approach (50).
However, the rifampin- and ofloxacin-resistant parents that we
isolated for these crosses exhibited altered persistence phenotypes,
consistent with previous reports that endogenous C. trachomatis
antibiotic resistance alleles can have phenotypic costs (51–54).
Our experience suggests that counterselection LGT performs op-
timally when mutants have strong phenotypes, and further refine-
ment of the counterselection approach may allow us to map the
remaining mutants in the future (41).
Kari et al. reported that trachoma isolates that lack tryptophan
synthase and a C. trachomatis serovar D trpB null mutant can be
fully reactivated from IFN--induced persistence with tryptophan
(47). In contrast, the IFN- sensitivity of our TrpBP221S mutant
was reversed when tryptophan was added to the cell culture me-
dium prior to, but not after, the time point at which IFN- per-
sistence was induced (Fig. 6B). This could indicate that aspects of
the persistence models used in our study and the study by Kari et
al. differed or that the TrpBP221S mutation causes production of a
TrpB protein with an altered function. We were unable to com-
pare the phenotypes of the TrpBP221S mutant, the serovar D TrpB
null mutant studied by Kari et al. (47), and a C. trachomatis L2
trpA allelic exchange mutant recently described by the Fields
group (55) directly because the growth rates of these strains differ
substantially (data not shown). However, C. trachomatis trpBA
expression is normally tightly repressed by TrpR in the presence of
tryptophan (20, 47, 56, 57). Since we observed that more
TrpBP221S genomes accumulated in the tryptophan reactivation
experiments than in the indole reactivation experiments (Fig. 8),
this supports the hypothesis that TrpBP221S might be toxic. It has
been previously shown that Salmonella enterica serovar Typhimu-
rium tryptophan synthase can produce ammonia and pyruvate
from serine by a -elimination reaction in the absence of indole
(31). We speculate that TrpBP221S may not be able to bind indole
but may still be able to produce ammonia, based on a hypothesis
that Aiyar and colleagues proposed to explain the inactivation of
tryptophan synthase in independent trachoma lineages (31). Fu-
ture studies will determine if the mutant TrpB is associated with
altered catalysis of the serine-indole condensation and -elimina-
tion reactions.
In addition to the predicted trpB mutant, we identified genes
not previously understood to be involved in IFN- persistence.
CTL0225 and a potential paralog, CTL0226, are predicted to be
members of the small neutral amino acid transporter (SNAT)
family (58, 59). Highly conserved CTL0225 orthologs are present
in all sequenced Chlamydia spp. (89% identity), and the closest
homologs outside the Chlamydia genus are 30%-identical hy-
pothetical proteins in Buchnera andCoxiella spp. (60). SNAT pro-
teins are predicted to be dimer-forming inner membrane pro-
teins that usually contain 6 transmembrane domains (59, 61).
TMHMM Server 2.0 analysis suggests that CTL0225G77E would
have altered topology and lack a transmembrane domain present
in native CTL0225 (see Fig. S4 in the supplemental material) (62).
SnatA, the only characterized SNAT protein, was identified in a
search for amino acid transporters of Thermococcus sp. strain
KS-1, a thermophilic archaeon that is auxotrophic for several
amino acids (59). Recombinant Thermococcus sp. strain KS-1
SnatA permitted growth of an Escherichia coli glycine/D-alanine
transporter (cycA) mutant on minimal alanine medium (59).
SnatA also mediated high-affinity energy- and proton-dependent
glycine transport that was inhibited by a variety of neutral amino
acids, including tryptophan (59). Chlamydia spp. are auxotrophic
for numerous amino acids and respond to amino acid starvation
by forming aberrant RBs (7). Paradoxically, high concentrations
of leucine, isoleucine, methionine, and phenylalanine can also
trigger formation of aberrant RBs that can be reactivated by valine
addition (49). In this case, valine starvation appears to be medi-
ated by amino acid antagonism for the chlamydial branched-
chain amino acid transporter BrnQ (49). Interestingly, we ob-
served that CTL0225G77E, but not the other Sip mutants, was also
sensitive to excess isoleucine (see Fig. S4) and our preliminary
results suggest that this phenotype can be reversed by valine addi-
tion (data not shown). Thus, we hypothesize that CTL0225 is an
amino acid transporter that is dispensable under normal growth
conditions but not during persistence under conditions in which
amino acids other than tryptophan may be limiting. The identifi-
cation of additional CTL0225 substrates could determine if this
protein plays a narrow accessory role in tryptophan metabolism
or a broader role in acquisition of amino acids whose availability is
restricted by the presence of IFN-.
CTL0694 is a hypothetical oxidoreductase that shares protein
homology (28%) with E. coli CysJ (60). The canonical function of
E. coli CysJ is in the sulfite reduction pathway (63), but C. tracho-
matis appears to lack all of the other enzymes in this pathway
except for CysQ (60). E. coli CysJ can also interact with YcbX (64)
to reduce 6-N-hydroxylaminopurine, a powerful mutagen, to ad-
enine (65). In this complex, CysJ provides the necessary reducing
equivalents to the molybdenum cofactor in YcbX (65), but CysJ-
like redox proteins have also been hypothesized to provide
reducing equivalents to multiple acceptor proteins (66). Simi-
lar N-hydroxylated-compound-detoxification systems have
been identified in organisms as diverse as humans (67) and green
algae (68). Oxidative radicals promote generation of hydroxylated
nucleobases (69). Knockdown of mitochondrial amidoxime re-
ducing component 2 sensitizes HeLa cells to aminopurine (70),
indicating that HeLa cells constitutively express machinery to
cope with hydroxylated aminopurines. IFN- treatment also ele-
vates generation of oxidative radicals (71), suggesting that this
could lead to the generation of hydroxylated nucleobases in IFN-
-treated HeLa cells. Since Chlamydia spp. scavenge ribonucle-
otide triphosphates from their hosts and cannot synthesize pu-
rines and pyrimidines (72), they may need to cope with
endogenously generated as well as imported hydroxylated nucleo-
bases. We hypothesize that the reduced size of CTL0694P105L in-
clusions under IFN--plus-tryptophan conditions could reflect
DNA damage and altered protein production. Additionally, the
disparity between CTL0694P105L genome accumulation and EB
production in reactivation experiments could indicate that ge-
nome replication continues but produces damaged chromosomes
leading to fewer infectious EBs and that this is may also be inde-
pendent of inclusion size. The function of CTL0694 and its poten-
tial interaction partner(s) in chlamydia will need to be determined
in future studies.
In summary, C. trachomatis survival and reactivation during
IFN- persistence are not solely mediated by tryptophan synthase.
The genes identified in the screen could open new lines of inves-
tigation that alter the classical view of chlamydial persistence. Ex-
tending our approach by generating a larger mutant library could
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help to uncover additional genes that play roles in persistence.
Testing if these genes contribute to C. trachomatis pathogenesis
would be ideal, but this not feasible with all of the genes due to the
lack of a relevant animal model. However, since CTL0225 and
CTL0694 are highly conserved in other Chlamydia spp., including
C. muridarum, a future direction would be to test if these genes
contribute to chlamydial survival and pathogenesis in mice.
ACKNOWLEDGMENTS
We thank Jeffrey Chang, Stan Spinola, Richard Morrison, Raphael Val-
divia, and Byron Batteiger and members of the Nelson laboratory for their
help in reviewing drafts of the manuscript and experimental advice.
Work described in this article was supported by NIH grant AI099278
to D.E.N. The funding agency had no role in study design, data collection
and interpretation, or the decision to submit the work for publication.
FUNDING INFORMATION
This work, including the efforts of David E. Nelson, was funded by HHS |
National Institutes of Health (NIH) (AI099278).
REFERENCES
1. Moulder JW. 1985. Comparative biology of intracellular parasitism. Mi-
crobiol Rev 49:298 –337.
2. Hybiske K, Stephens RS. 2007. Mechanisms of host cell exit by the intra-
cellular bacterium Chlamydia. Proc Natl Acad Sci U S A 104:11430 –
11435. http://dx.doi.org/10.1073/pnas.0703218104.
3. Lewis ME, Belland RJ, AbdelRahman YM, Beatty WL, Aiyar AA, Zea
AH, Greene SJ, Marrero L, Buckner LR, Tate DJ, McGowin CL, Koz-
lowski PA, O’Brien M, Lillis RA, Martin DH, Quayle AJ. 2014. Mor-
phologic and molecular evaluation of Chlamydia trachomatis growth in
human endocervix reveals distinct growth patterns. Front Cell Infect Mi-
crobiol 4:71. http://dx.doi.org/10.3389/fcimb.2014.00071.
4. Hanna L, Merigan TC, Jawetz E. 1966. Inhibition of TRIC agents by
virus-induced interferon. Proc Soc Exp Biol Med 122:417– 421. http://dx
.doi.org/10.3181/00379727-122-31150.
5. Shemer-Avni Y, Wallach D, Sarov I. 1988. Inhibition of Chlamydia
trachomatis growth by recombinant tumor necrosis factor. Infect Immun
56:2503–2506.
6. Byrne GI, Lehmann LK, Landry GJ. 1986. Induction of tryptophan
catabolism is the mechanism for gamma-interferon-mediated inhibition
of intracellular Chlamydia psittaci replication in T24 cells. Infect Immun
53:347–351.
7. Coles AM, Reynolds DJ, Harper A, Devitt A, Pearce JH. 1993. Low-
nutrient induction of abnormal chlamydial development: a novel compo-
nent of chlamydial pathogenesis? FEMS Microbiol Lett 106:193–200. http:
//dx.doi.org/10.1111/j.1574-6968.1993.tb05958.x.
8. Raulston JE. 1997. Response of Chlamydia trachomatis serovar E to iron
restriction in vitro and evidence for iron-regulated chlamydial proteins.
Infect Immun 65:4539 – 4547.
9. Thompson CC, Carabeo RA. 2011. An optimal method of iron starvation
of the obligate intracellular pathogen, Chlamydia trachomatis. Front Mi-
crobiol 2:20.
10. Deka S, Vanover J, Dessus-Babus S, Whittimore J, Howett MK, Wyrick
PB, Schoborg RV. 2006. Chlamydia trachomatis enters a viable but non-
cultivable (persistent) state within herpes simplex virus type 2 (HSV-2)
co-infected host cells. Cell Microbiol 8:149 –162. http://dx.doi.org/10
.1111/j.1462-5822.2005.00608.x.
11. Matsumoto A, Manire GP. 1970. Electron microscopic observations on
the fine structure of cell walls of Chlamydia psittaci. J Bacteriol 104:1332–
1337.
12. Kramer MJ, Gordon FB. 1971. Ultrastructural analysis of the effects of
penicillin and chlortetracycline on the development of a genital tractChla-
mydia. Infect Immun 3:333–341.
13. Wyrick PB. 2010.Chlamydia trachomatis persistence in vitro: an overview.
J Infect Dis 201(Suppl 2):S88 –S95.
14. Schneider WM, Chevillotte MD, Rice CM. 2014. Interferon-stimulated
genes: a complex web of host defenses. Annu Rev Immunol 32:513–545.
http://dx.doi.org/10.1146/annurev-immunol-032713-120231.
15. Meunier E, Broz P. 2016. Interferon-inducible GTPases in cell autono-
mous and innate immunity. Cell Microbiol 18:168 –180. http://dx.doi.org
/10.1111/cmi.12546.
16. Beatty WL, Byrne GI, Morrison RP. 1993. Morphologic and antigenic
characterization of interferon gamma-mediated persistentChlamydia tra-
chomatis infection in vitro. Proc Natl Acad Sci U S A 90:3998 – 4002. http:
//dx.doi.org/10.1073/pnas.90.9.3998.
17. Yasui H, Takai K, Yoshida R, Hayaishi O. 1986. Interferon enhances
tryptophan metabolism by inducing pulmonary indoleamine 2,3-
dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci
U S A 83:6622– 6626. http://dx.doi.org/10.1073/pnas.83.17.6622.
18. Belland RJ, Nelson DE, Virok D, Crane DD, Hogan D, Sturdevant D,
Beatty WL, Caldwell HD. 2003. Transcriptome analysis of chlamydial
growth during IFN-gamma-mediated persistence and reactivation. Proc
Natl Acad Sci U S A 100:15971–15976. http://dx.doi.org/10.1073/pnas
.2535394100.
19. Morrison RP. 2000. Differential sensitivities of Chlamydia trachomatis
strains to inhibitory effects of gamma interferon. Infect Immun 68:6038 –
6040. http://dx.doi.org/10.1128/IAI.68.10.6038-6040.2000.
20. Caldwell HD, Wood H, Crane D, Bailey R, Jones RB, Mabey D,
Maclean I, Mohammed Z, Peeling R, Roshick C, Schachter J, Solomon
AW, Stamm WE, Suchland RJ, Taylor L, West SK, Quinn TC, Belland
RJ, McClarty G. 2003. Polymorphisms in Chlamydia trachomatis trypto-
phan synthase genes differentiate between genital and ocular isolates. J
Clin Invest 111:1757–1769. http://dx.doi.org/10.1172/JCI17993.
21. Fehlner-Gardiner C, Roshick C, Carlson JH, Hughes S, Belland RJ,
Caldwell HD, McClarty G. 2002. Molecular basis defining human Chla-
mydia trachomatis tissue tropism. A possible role for tryptophan synthase.
J Biol Chem 277:26893–26903.
22. Carlson JH, Porcella SF, McClarty G, Caldwell HD. 2005. Comparative
genomic analysis of Chlamydia trachomatis oculotropic and genitotropic
strains. Infect Immun 73:6407– 6418. http://dx.doi.org/10.1128/IAI.73.10
.6407-6418.2005.
23. Harris SR, Clarke IN, Seth-Smith HM, Solomon AW, Cutcliffe LT,
Marsh P, Skilton RJ, Holland MJ, Mabey D, Peeling RW, Lewis DA,
Spratt BG, Unemo M, Persson K, Bjartling C, Brunham R, de Vries HJ,
Morre SA, Speksnijder A, Bebear CM, Clerc M, de Barbeyrac B, Parkhill
J, Thomson NR. 2012. Whole-genome analysis of diverse Chlamydia
trachomatis strains identifies phylogenetic relationships masked by cur-
rent clinical typing. Nat Genet 44:413– 419. http://dx.doi.org/10.1038/ng
.2214.
24. Stephens RS, Kalman S, Lammel C, Fan J, Marathe R, Aravind L,
Mitchell W, Olinger L, Tatusov RL, Zhao Q, Koonin EV, Davis RW.
1998. Genome sequence of an obligate intracellular pathogen of humans:
Chlamydia trachomatis. Science 282:754 –759. http://dx.doi.org/10.1126
/science.282.5389.754.
25. Sasaki-Imamura T, Yoshida Y, Suwabe K, Yoshimura F, Kato H. 2011.
Molecular basis of indole production catalyzed by tryptophanase in the
genus Prevotella. FEMS Microbiol Lett 322:51–59. http://dx.doi.org/10
.1111/j.1574-6968.2011.02329.x.
26. Romanik M, Martirosian G, Wojciechowska-Wieja A, Cieslik K, Ka-
zmierczakW. 2007. Co-occurence of indol-producing bacterial strains in
the vagina of women infected with Chlamydia trachomatis. Ginekol Pol
78:611– 615. (In Polish.)
27. Lloyd D, Lauritsen FR, Degn H. 1991. The parasitic flagellates Trichomo-
nas vaginalis and Tritrichomonas foetus produce indole and dimethyl dis-
ulphide: direct characterization by membrane inlet tandem mass spec-
trometry. J Gen Microbiol 137:1743–1747. http://dx.doi.org/10.1099
/00221287-137-7-1743.
28. Brotman RM, Klebanoff MA, Nansel TR, Yu KF, Andrews WW, Zhang
J, Schwebke JR. 2010. Bacterial vaginosis assessed by Gram stain and
diminished colonization resistance to incident gonococcal, chlamydial,
and trichomonal genital infection. J Infect Dis 202:1907–1915. http://dx
.doi.org/10.1086/657320.
29. Fredricks DN, Fiedler TL, Marrazzo JM. 2005. Molecular identification
of bacteria associated with bacterial vaginosis. N Engl J Med 353:1899 –
1911. http://dx.doi.org/10.1056/NEJMoa043802.
30. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL,
Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC,
Ault K, Peralta L, Forney LJ. 2011. Vaginal microbiome of reproductive-
age women. Proc Natl Acad Sci U S A 108(Suppl 1):4680 – 4687. http://dx
.doi.org/10.1073/pnas.1002611107.
31. Aiyar A, Quayle AJ, Buckner LR, Sherchand SP, Chang TL, Zea AH,
Martin DH, Belland RJ. 2014. Influence of the tryptophan-indole-
Chlamydia Persistence Genes
October 2016 Volume 84 Number 10 iai.asm.org 2799Infection and Immunity
IFNgamma axis on human genital Chlamydia trachomatis infection: role
of vaginal co-infections. Front Cell Infect Microbiol 4:72. http://dx.doi
.org/10.3389/fcimb.2014.00072.
32. McClarty G, Caldwell HD, Nelson DE. 2007. Chlamydial interferon
gamma immune evasion influences infection tropism. Curr Opin Micro-
biol 10:47–51. http://dx.doi.org/10.1016/j.mib.2006.12.003.
33. Nelson DE, Virok DP, Wood H, Roshick C, Johnson RM, Whitmire
WM, Crane DD, Steele-Mortimer O, Kari L, McClarty G, Caldwell HD.
2005. Chlamydial IFN-gamma immune evasion is linked to host infection
tropism. Proc Natl Acad Sci U S A 102:10658 –10663. http://dx.doi.org/10
.1073/pnas.0504198102.
34. Thomas SM, Garrity LF, Brandt CR, Schobert CS, Feng GS, Taylor
MW, Carlin JM, Byrne GI. 1993. IFN-gamma-mediated antimicrobial
response. Indoleamine 2,3-dioxygenase-deficient mutant host cells no
longer inhibit intracellular Chlamydia spp. or Toxoplasma growth. J Im-
munol 150:5529 –5534.
35. Kari L, Whitmire WM, Carlson JH, Crane DD, Reveneau N, Nelson
DE, Mabey DC, Bailey RL, Holland MJ, McClarty G, Caldwell HD.
2008. Pathogenic diversity amongChlamydia trachomatis ocular strains in
nonhuman primates is affected by subtle genomic variations. J Infect Dis
197:449 – 456. http://dx.doi.org/10.1086/525285.
36. Tietzel I, El-Haibi C, Carabeo RA. 2009. Human guanylate binding
proteins potentiate the anti-chlamydia effects of interferon-gamma. PLoS
One 4:e6499. http://dx.doi.org/10.1371/journal.pone.0006499.
37. Al-Zeer MA, Al-Younes HM, Lauster D, Abu Lubad M, Meyer TF. 2013.
Autophagy restricts Chlamydia trachomatis growth in human macro-
phages via IFNG-inducible guanylate binding proteins. Autophagy 9:50 –
62. http://dx.doi.org/10.4161/auto.22482.
38. Johnston AC, Piro A, Clough B, Siew M, Virreira Winter S, Coers J,
Frickel EM. 10 March 2016. Human GBP1 does not localize to pathogen
vacuoles but restricts Toxoplasma gondii. Cell Microbiol http://dx.doi.org
/10.1111/cmi.12579.
39. Rajaram K, Nelson DE. 2015. Chlamydia muridarum infection of mac-
rophages elicits bactericidal nitric oxide production via reactive oxygen
species and cathepsin B. Infect Immun 83:3164 –3175. http://dx.doi.org
/10.1128/IAI.00382-15.
40. Wang Y, Kahane S, Cutcliffe LT, Skilton RJ, Lambden PR, Clarke IN.
2011. Development of a transformation system for Chlamydia trachoma-
tis: restoration of glycogen biosynthesis by acquisition of a plasmid shuttle
vector. PLoS Pathog 7:e1002258. http://dx.doi.org/10.1371/journal.ppat
.1002258.
41. Brothwell JA, Muramatsu MK, Toh E, Rockey DD, Putman TE, Barta
ML, Hefty PS, Suchland RJ, Nelson DE. 13 July 2016. Interrogating genes
that mediate Chlamydia trachomatis survival in cell culture using condi-
tional mutants and recombination. J Bacteriol http://dx.doi.org/10.1128
/JB.00161-16.
42. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietz-
sch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White
DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an
open-source platform for biological-image analysis. Nat Methods 9:676 –
682. http://dx.doi.org/10.1038/nmeth.2019.
43. Rajaram K, Giebel AM, Toh E, Hu S, Newman JH, Morrison SG, Kari
L, Morrison RP, Nelson DE. 2015. Mutational analysis of the Chlamydia
muridarum plasticity zone. Infect Immun 83:2870 –2881. http://dx.doi
.org/10.1128/IAI.00106-15.
44. Matsumoto A, Izutsu H, Miyashita N, Ohuchi M. 1998. Plaque forma-
tion by and plaque cloning of Chlamydia trachomatis biovar trachoma. J
Clin Microbiol 36:3013–3019.
45. Putman TE, Suchland RJ, Ivanovitch JD, Rockey DD. 2013. Culture-
independent sequence analysis of Chlamydia trachomatis in urogenital
specimens identifies regions of recombination and in-patient sequence
mutations. Microbiology 159:2109 –2117. http://dx.doi.org/10.1099/mic
.0.070029-0.
46. Leonhardt RM, Lee SJ, Kavathas PB, Cresswell P. 2007. Severe trypto-
phan starvation blocks onset of conventional persistence and reduces re-
activation of Chlamydia trachomatis. Infect Immun 75:5105–5117. http:
//dx.doi.org/10.1128/IAI.00668-07.
47. Kari L, Goheen MM, Randall LB, Taylor LD, Carlson JH, Whitmire
WM, Virok D, Rajaram K, Endresz V, McClarty G, Nelson DE,
Caldwell HD. 2011. Generation of targeted Chlamydia trachomatis null
mutants. Proc Natl Acad Sci U S A 108:7189 –7193. http://dx.doi.org/10
.1073/pnas.1102229108.
48. Gérard HC, Krausse-Opatz B, Wang Z, Rudy D, Rao JP, Zeidler H,
Schumacher HR, Whittum-Hudson JA, Köhler L, Hudson AP. 2001.
Expression of Chlamydia trachomatis genes encoding products required
for DNA synthesis and cell division during active versus persistent infec-
tion. Mol Microbiol 41:731–741. http://dx.doi.org/10.1046/j.1365-2958
.2001.02550.x.
49. Braun PR, Al-Younes H, Gussmann J, Klein J, Schneider E, Meyer TF.
2008. Competitive inhibition of amino acid uptake suppresses chlamydial
growth: involvement of the chlamydial amino acid transporter BrnQ. J
Bacteriol 190:1822–1830. http://dx.doi.org/10.1128/JB.01240-07.
50. Suchland RJ, Sandoz KM, Jeffrey BM, Stamm WE, Rockey DD. 2009.
Horizontal transfer of tetracycline resistance among Chlamydia spp. in
vitro. Antimicrob Agents Chemother 53:4604 – 4611. http://dx.doi.org/10
.1128/AAC.00477-09.
51. Binet R, Maurelli AT. 2009. The chlamydial functional homolog of KsgA
confers kasugamycin sensitivity to Chlamydia trachomatis and impacts
bacterial fitness. BMC Microbiol 9:279. http://dx.doi.org/10.1186/1471
-2180-9-279.
52. Binet R, Maurelli AT. 2005. Fitness cost due to mutations in the 16S
rRNA associated with spectinomycin resistance inChlamydia psittaci 6BC.
Antimicrob Agents Chemother 49:4455– 4464. http://dx.doi.org/10.1128
/AAC.49.11.4455-4464.2005.
53. Binet R, Maurelli AT. 2007. Frequency of development and associated
physiological cost of azithromycin resistance in Chlamydia psittaci 6BC
and C. trachomatis L2. Antimicrob Agents Chemother 51:4267– 4275.
http://dx.doi.org/10.1128/AAC.00962-07.
54. Binet R, Bowlin AK, Maurelli AT, Rank RG. 2010. Impact of azithro-
mycin resistance mutations on the virulence and fitness of Chlamydia
caviae in guinea pigs. Antimicrob Agents Chemother 54:1094 –1101. http:
//dx.doi.org/10.1128/AAC.01321-09.
55. Mueller KE, Wolf K, Fields KA. 2016. Gene deletion by fluorescence-
reported allelic exchange mutagenesis in Chlamydia trachomatis. mBio
7(1):e01817-15. http://dx.doi.org/10.1128/mBio.01817-15.
56. Carlson JH, Wood H, Roshick C, Caldwell HD, McClarty G. 2006. In
vivo and in vitro studies of Chlamydia trachomatis TrpR:DNA interac-
tions. Mol Microbiol 59:1678 –1691. http://dx.doi.org/10.1111/j.1365
-2958.2006.05045.x.
57. Akers JC, Tan M. 2006. Molecular mechanism of tryptophan-dependent
transcriptional regulation in Chlamydia trachomatis. J Bacteriol 188:
4236 – 4243. http://dx.doi.org/10.1128/JB.01660-05.
58. Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chitsaz F, Geer
LY, Geer RC, He J, Gwadz M, Hurwitz DI, Lanczycki CJ, Lu F, Marchler
GH, Song JS, Thanki N, Wang Z, Yamashita RA, Zhang D, Zheng C,
Bryant SH. 2015. CDD: NCBI’s conserved domain database. Nucleic Ac-
ids Res 43:D222–D226. http://dx.doi.org/10.1093/nar/gku1221.
59. Akahane S, Kamata H, Yagisawa H, Hirata H. 2003. A novel neutral
amino acid transporter from the hyperthermophilic archaeonThermococ-
cus sp. KS-1. J Biochem 133:173–180.
60. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W,
Lipman DJ. 1997. Gapped BLAST and PSI-BLAST: a new generation of
protein database search programs. Nucleic Acids Res 25:3389 –3402. http:
//dx.doi.org/10.1093/nar/25.17.3389.
61. Tsu BV, Saier MH, Jr. 2015. The LysE superfamily of transport proteins
involved in cell physiology and pathogenesis. PLoS One 10:e0137184.
http://dx.doi.org/10.1371/journal.pone.0137184.
62. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. 2001. Predicting
transmembrane protein topology with a hidden Markov model: applica-
tion to complete genomes. J Mol Biol 305:567–580. http://dx.doi.org/10
.1006/jmbi.2000.4315.
63. Eschenbrenner M, Coves J, Fontecave M. 1995. The flavin reductase
activity of the flavoprotein component of sulfite reductase from Esche-
richia coli. A new model for the protein structure. J Biol Chem 270:20550 –
20555.
64. Li C, Peck HD, Jr, Przybyla AE. 1987. Cloning of the 3=-phosphoadenylyl
sulfate reductase and sulfite reductase genes from Escherichia coli K-12.
Gene 53:227–234. http://dx.doi.org/10.1016/0378-1119(87)90011-4.
65. Kozmin SG, Wang J, Schaaper RM. 2010. Role for CysJ flavin reductase
in molybdenum cofactor-dependent resistance of Escherichia coli to 6-N-
hydroxylaminopurine. J Bacteriol 192:2026 –2033. http://dx.doi.org/10
.1128/JB.01438-09.
66. White RH. 2010. The twists and turns of enzyme function. J Bacteriol
192:2023–2025. http://dx.doi.org/10.1128/JB.00087-10.
67. Havemeyer A, Grunewald S, Wahl B, Bittner F, Mendel R, Erdelyi P,
Fischer J, Clement B. 2010. Reduction of N-hydroxy-sulfonamides, in-
Muramatsu et al.
2800 iai.asm.org October 2016 Volume 84 Number 10Infection and Immunity
cluding N-hydroxy-valdecoxib, by the molybdenum-containing enzyme
mARC. Drug Metab Dispos 38:1917–1921. http://dx.doi.org/10.1124
/dmd.110.032813.
68. Chamizo-Ampudia A, Galvan A, Fernandez E, Llamas A. 2011. The Chla-
mydomonas reinhardtii molybdenum cofactor enzyme crARC has a Zn-
dependent activity and protein partners similar to those of its human homo-
logue. Eukaryot Cell 10:1270–1282. http://dx.doi.org/10.1128/EC.05096-11.
69. Simandan T, Sun J, Dix TA. 1998. Oxidation of DNA bases, deoxyribo-
nucleosides and homopolymers by peroxyl radicals. Biochem J 335(Pt
2):233–240. http://dx.doi.org/10.1042/bj3350233.
70. Plitzko B, Havemeyer A, Kunze T, Clement B. 2015. The pivotal role of
the mitochondrial amidoxime reducing component 2 in protecting hu-
man cells against apoptotic effects of the base analog N6-
hydroxylaminopurine. J Biol Chem 290:10126 –10135. http://dx.doi.org
/10.1074/jbc.M115.640052.
71. Aune TM, Pogue SL. 1989. Inhibition of tumor cell growth by interferon-
gamma is mediated by two distinct mechanisms dependent upon oxygen
tension: induction of tryptophan degradation and depletion of intracellu-
lar nicotinamide adenine dinucleotide. J Clin Invest 84:863– 875. http://dx
.doi.org/10.1172/JCI114247.
72. Tipples G, McClarty G. 1993. The obligate intracellular bacterium Chla-
mydia trachomatis is auxotrophic for three of the four ribonucleoside
triphosphates. Mol Microbiol 8:1105–1114. http://dx.doi.org/10.1111/j
.1365-2958.1993.tb01655.x.
Chlamydia Persistence Genes
October 2016 Volume 84 Number 10 iai.asm.org 2801Infection and Immunity
